Axium Healthcare Pharmacy Puerto Rico is proud to announce it is now dispensing XPOVIO (selinexor) tablets, for oral use for the treatment. This nuclear export inhibitor (XPO1) is indicated:
Milton Latoni, VP of Sales & Business Development for Axium Healthcare Pharmacy Puerto Rico, recently shared what access to XPOVIO means for oncology patients in PR. “We continue adding recently FDA-approved therapies to our extensive oncology limited distribution drug portfolio. Healthcare professionals continue to prescribe new treatment options and, as the leading specialty pharmacy, we can provide local service to the island’s population. We are proud to add XPOVIO to our treatment options for patients who have not responded to previous treatments.”
At Axium Healthcare Pharmacy Puerto Rico our clinical and care teams have extensive experience with the treatment challenges that can arise when dealing with Oncology. We are passionate about simplifying the enrollment process for our patients by providing comprehensive financial services and personalized patient care support.
Axium Healthcare Pharmacy Puerto Rico:
At Axium Healthcare Pharmacy Puerto Rico, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As a leading specialty pharmacy, Axium Healthcare Pharmacy Puerto Rico offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Dermatology, HIV, Hepatitis C, Oncology, Multiple Sclerosis, Movement Disorders, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, Rare Diseases plus others. Axium Healthcare Pharmacy Puerto Rico services patients island-wide and is ACHC (since 2010) and URAC Accredited (since 2016). Axium's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.axiumpr.com.
About Karyopharm Therapeutics:
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com or follow on Twitter and LinkedIn at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.